Expert content for key biopharmaceutical decisions

Rapid insights into critical deal making trends to uncover nuances in specific deal types.

Whether you are looking to buy, sell, or license a drug candidate, our gold standard biopharma deals intelligence gives you insight to support your own deals. Thomson Reuters Recap offers you rapid insight into critical deal making trends and allows you to uncover nuances in specific deal comparables.

Search for potential partners, conduct due diligence, assess deal value, explore deal structures and terms, and determine statistical technical success rates. From broad market wide trends to tightly focused comparables, Recap helps you make better decisions faster.

Features & Benefits

  • Over 40,000 hand curated deal records that are updated daily, including press releases, SEC filed contracts, and clinical trials data.
  • Unredacted contracts, acquired through FOIA requests, give you a complete view into the commercial details including post commercialization royalty rates.
  • Determine how much an asset is worth.
  • Evaluate the right time to license your asset in the drug development process.

Explore the Dealmaker's Playbook: drawing on BioWorld, Cortellis Competitive Intelligence, and Recap to give you the full picture on the potential deals across the life sciences.


Related Blog Posts

fda-approval-and-regulation-of-medical-devices-a-primer
20 November, 2016

FDA approval and regulation of medical devices: a primer

Regulatory Affairs
when-competitive-intelligence-is-predictive-rather-than-reactive-biopharma-companies-can-grab-the-edge
20 November, 2016

When competitive intelligence is predictive rather than reactive, biopharma companies can grab the edge

Research and Development
ngs-maybe-sort-of-sometimes-clinic-ready
20 November, 2016

NGS, maybe, sort of, sometimes clinic ready

Research and Development